Search Within

GME, Medicine

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (146)
  2. Journal Article (143)
  3. Research Letter (8)
  4. Review (4)
  5. Editorial (3)
Groups
  1. Graduate Medical Education (304)
  2. Human Oncology and Pathogenesis Program (304)
  3. GSK Faculty (300)
  4. Department of Medicine (290)
  5. Hematology-Oncology Fellows (247)
  6. Solid Tumor Oncology Division (202)

More Groups

People
  1. Michael Berger (67)
  2. Nikolaus Schultz (53)
  3. Marc Ladanyi (48)
  4. Marcel Van Den Brink (40)
  5. David Solit (35)
  6. Santosha Vardhana (34)

More People

Years
  1. 2025 (21)
  2. 2024 (75)
  3. 2023 (81)
  4. 2022 (53)
  5. 2021 (17)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Blood (31)
  3. Clinical Cancer Research (20)
  4. Cancer Research (17)
  5. Annals of Oncology (12)
  6. JCO Precision Oncology (10)

More Publications

Publishers
  1. American Society of Clinical Oncology (78)
  2. American Association for Cancer Research (45)
  3. American Society of Hematology (35)
  4. Elsevier Inc. (29)
  5. Nature Publishing Group (24)
  6. Oxford University Press (24)

More Publishers

Results (304)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis
    Meeting Abstract

    Harrold, E.; Walch, H. S.; Chatila, W. K.; Kemel, Y.; Borio, M.; Maio, A.; Khurram, A.; Salo-Mullen, E. E.; Latham, A.; Murciano-Goroff, Y. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Redefining early-onset cancer and risk of hereditary cancer predisposition
    Meeting Abstract

    Stadler, Z. K.; Maio, A.; Khurram, A.; Kemel, Y.; Padunan, A.; Borio, M.; Sheehan, M.; Murciano-Goroff, Y. R.; Walsh, M. F.; Will, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Luo, J.; Alessi, J. V. M.; Pecci, F.; Lamberti, G.; Hong, Lingzhi; Plodkowski, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer
    Meeting Abstract

    Arbour, K. C.; Thummalapalli, R.; Bernstein, E.; Herzberg, B.; Li, B. T.; Iqbal, A.; Santini, F. C.; Eng, J.; Ladanyi, M.; Yang, S. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC)
    Meeting Abstract

    Keane, F.; Saadat, L.; O'Connor, C.; Chou, J. F.; Brannon, A. R.; Cowzer, D.; Crowley, F.; Debnath, N.; Bowman, A.; Xu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Solit, D. B.; Walch, H. S.; Chatila, W. K.; Maron, S. B.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Schultz, N.; Berger, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis
    Meeting Abstract

    Dankner, M.; Petrecca, S.; Fabi, F.; Nowakowski, A.; Rajadurai, C. V.; Rousselle, E.; Stein, A.; Bian, D. J.; Tai, P.; Belaiche, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
    Meeting Abstract

    Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save